Linagliptin as Add on to Basal Insulin in the Elderly
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
placebo
linagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation and Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial.
- Male and female patients with a clinical diagnosis of Type 2 Diabetes Mellitus, at the time of Informed Consent, who are:
- 60 years of age or older at informed consent or Screen Visit,
- taking stable doses of basal or biosimilar basal insulin [strictly inclusive of: insulin neutral protamine Hagedorn and isophane insulin; Humalog Basal (a suspension of insulin lispro protamine); insulin degludec; insulin detemir; and insulin glargine] for at least 4 weeks prior to randomisation (Visit 3) with dose adjustments up to a maximum of plus or minus 20% of baseline being allowed,
- may or may not be taking metformin immediate release or extended release [if the patient is taking metformin, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)], and
- may or may not be taking alpha-glucosidase inhibitors [acarbose, miglitol, and voglibose; if the patient is taking alpha-glucosidase inhibitors, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)].
- Patients must have an glycosylated Haemoglobin of 7.0% (53 millimoles per mole) to 10.0% (86 millimoles per mole) at the first visit (Screen).
- Patients must have a Body Mass Index of 45 kilogram/meter squared or less at the Screen Visit.
- In the investigator's opinion, patients must be reliable, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them.
Exclusion criteria:
- Impaired cognitive ability as supported by the Saint Louis University Mental Status Examination, additional assessment if necessary, and verified by the investigator at the Screen Visit.
- Depressed mood as supported by a score of 10 or more on the Patient Health Questionnaire at the Screen Visit.
- Type 1 Diabetes Mellitus as determined by past medical records and history.
- Acute coronary syndrome (non-ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, and/or unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to Screen Visit.
- Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the upper limit of normal in any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.
- Bariatric, gastric bypass, and other gastrointestinal procedures or surgeries (including all types of gastric banding, restriction, and/or LapBand) with the objective of promoting weight loss within the past two years at Screen Visit.
- Medical history of cancer (except for resected non-invasive basal or squamous cell carcinoma) and/or treatment for cancer within the last 5 years.
- Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (malaria, babesiosis, haemolytic anaemia).
Sites / Locations
- Syed Research Consultants, LLC
- Precision Research Institute, LLC
- Aurora Care Clinic, LLC
- Prime Care Clinical Research
- Torrance Clinical Research Institute Inc.
- Internal Medicine of the Rockies
- Cohen Medical Research Associates, LLC
- Riverside Clinical Research
- Clinical Research of Hollywood
- East Coast Institute for Research LLC at NE FL Endo & Diabetes
- Solutions Through Advanced Research, Inc.
- Panax Clinical Research
- Baptist Diabetes Associates, PA
- International Research Associates
- South Florida Research Solutions, LLC
- Georgia Clinical Research, LLC
- Midwest Endocrinology
- American Health Network
- Accent Clinical Trials
- Clinical Research of South Nevada
- Manhattan Medical Research Practice PLLC
- Family Practice Center of Wadsworth, Inc.
- Clinical Research Associates of Central Pennsylvania
- Fleetwood Clinical Research
- Preferred Primary Care Phys
- TLM Medical Services, LLC
- Advanced Research Associates
- Holston Medical Group
- Arlington Family Research Center, Inc.
- Renaissance Clinical Research and Hypertension of Texas
- Diabetes and Thyroid Center of Fort Worth
- Houston Clinical Research Associates
- Science Advancing Medicine Clinical Research Center
- Office of Dr. Val R. Hansen
- Millennium Clinical Trials LLC
- York Clinical Research, LLC
- Rowan Research, Inc.
- Family Medical Clinic
- AIM Centre
- Royal Brisbane & Women's Hospital-Endocrinology
- ECRU Maroondah
- Ham - PRAC Mortelmans
- CEQUIN
- Dexa Diabetes Servicios Médicos Ltda
- CAFAM Caja de Compensación Familiar
- Asociacion IPS Medicos Internistas de Caldas
- Hospital Pablo Tobón Uribe
- Aalborg Sygehus Syd
- Sydvestjyst Sygehus Esbjerg, Endokrinologisk afdeling
- Frederiksberg Hospital, Endokrinologisk afd.
- Gentofte University Hospital
- Kolding Sygehus
- Bispebjerg Hospital
- Køge Sygehus
- Roskilde Sygehus
- Keravan terveyskeskus
- Terveystalo Oulu, Diapolis
- Lääkärikeskus Aava, Turku
- TYKS
- Gemeinschaftspraxis, Asslar
- ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH
- Diabetologische Schwerpunktpraxis, Bosenheim
- Dünnwaldpraxis, Köln
- Praxis Dr. Naudts, Rodgau
- Praxis Dr. Braun, Unterschneidheim
- "Korgialeneio-Benakeio" Hellenic Red Cross Hospital
- General Hospital of Athens "G. Gennimatas"
- Univ. Gen. Hosp. of Ioannina
- General Hospital of Attiki "KAT-EKA"
- General Hospital of Nikaia
- General Hospital of Thessaloniki "G. Papanikolaou"
- Connolly Hospital Blanchardstown
- Daishinkai Medical Corporation Ookuma Hospital
- Matsuyama Shimin Hospital
- Iryohojin Kikuchi Naika Clinic
- Nakamura Digestive Organ Internal Medicine Clinic
- Iida Medical Clinic
- Jiyugaoka Yamada Clinic
- Shinkotoni family Clinic
- Yoshida Memorial Hospital
- Teine Keijinkai Clinic
- Japan Community Health Care Organization Hokkaido Hospital
- Itabashi Diabetic medicine and Dermatology Clinic
- Nakakinen Clinic
- Takai Naika Clinic
- Kaneshiro DIAB Clinic, Kanagawa, I.M.
- Asahi Med. clinic, Kanagawa, I.M.
- Ishikawa Med. Clinic, Kanagawa, I.M.
- National Hospital Organization Yokohama Medical Center
- Okayama Saiseikai General Hospital Outpatient Center
- AMC Nishi-umeda Clinic
- Nissay Hospital Nippon Life Saiseikai Public Interest Incorporated Foundation
- OCROM Clinic
- Saga Memorial Hospital
- Asano Clinic
- Hamamatsu Rosai Hospital
- Kuriyama Clinic
- The Institute for Adult Deseases, Asahi Life Foundation
- Tokyo-Eki Center-building Clinic
- Tokyo Center Clinic
- AGE Makita Medical Clinic
- Kobayashi Internal Medicine Clinic
- Kunitachi Naika Clinic
- Japanese Red Cross Medical Center
- Investigación en Salud y Metabolismo S.C.
- Centro de At. e Inv.en Fact.de riesgo cardiovasc.Omega, S.C.
- CAIMED
- Clinstile S.A. de C.V.
- CEDOPEC-Ctro Esp en Diab, Obesidad y Prev de Enf Cardiovasc
- Asociación Mexicana para la Investigacion Clínica, A.C(AMIC)
- South Pacific Clinical Trials
- Middlemore Clinical Trials
- Christchurch Hospital
- Medicome Sp. z o.o.
- Omedica Centrum Medyczne
- NBR Polska
- Nicodiab SRL, Bucharest
- Pelican Impex SRL, Cabinet Nr. 15
- Mediab SRL
- TREAD Research
- Tiervlei Trial Centre
- Paarl Research Centre
- Soweto Clinical Trials Centre
- LCS Clinical Research Unit
- Resego Health Services
- Zinakekele Medical Centre
- Mzansi Ethical Research Centre
- VX Pharma (Pty) Ltd Pretoria
- Hospital A Coruña
- Instituto de Ciencias Médicas
- Hospital Quiron. I.C.U.
- C.A.P. Sardenya
- CAP Les Corts
- CAP Canet de Mar
- Hospital Virgen de la Victoria
- Hospital Nuestra Señora de Valme
- Hospital Clínico de Valencia
- CAP El Remei
- The Haven Surgery
- South Axholme Practice
- Fowey Clinical Research Company Ltd
- Oak Tree Surgery
- St. Mary's Hospital, Vectasearch Clinic, Newport
- Mounts Bay Medical Ltd
- Rame Medical, Penntorr Health
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
linagliptin 5 mg
placebo
Arm Description
patient to receive a tablet of linagliptin 5 mg each day
patient to receive a tablet of placebo matching linagliptin 5 mg
Outcomes
Primary Outcome Measures
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.
This outcome has measured difference between HbA1c values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication. HbA1c is a form of hemoglobin, a blood pigment that carries oxygen, which is bound to glucose. The term HbA1c also refers to glycated hemoglobin. High levels of HbA1c (Normal range is less than 6%) indicate poorer control of diabetes than level in normal range.
Secondary Outcome Measures
Percentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.
Hypoglycaemia accompanied by a prespecified glucose value is defined as any investigator reported hypoglycaemia (event or AE) with a reported blood glucose level of less than 54 milligram/deciLitre (3.0 millimole/Litre) or any investigator reported symptomatic hypoglycaemic AE with a reported blood glucose level of less or equal 70 milligram/deciLitre (3.9millimole/Litre) or any severe hypoglycaemic AE. Severe hypoglycaemia is an event that requires the assistance of another person to actively administer carbohydrates or glucagon because the patient is unable to take the substance on his or her own. The confidence intervals mentioned in measure of dispersion are exact 95% confidence interval by Clopper and Pearson. The percentage of patients with at least one hypoglycaemia accompanied by a glucose value less than 54mg/dL alone has also represented separately according American Diabetes Association definition of clinically significant hypoglycaemia.
Percentage of Patients With HbA1c<8.0%
This is the percentage of patients with HbA1c on treatment <8.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Percentage of Patients With HbA1c on Treatment <7.0%
This is the percentage of patients with HbA1c on treatment <7.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Percentage of Patients With HbA1c Lowering by at Least 0.5%.
The percentage of patients who attained lowering of HbA1c by ≥0.5% from baseline after 24 weeks of treatment were analysed. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Change From Baseline in Fasting Plasma Glucose (FPG)
This outcome has measured difference between FPG values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication
Full Information
NCT ID
NCT02240680
First Posted
September 15, 2014
Last Updated
June 1, 2018
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT02240680
Brief Title
Linagliptin as Add on to Basal Insulin in the Elderly
Official Title
A 24 Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Once Daily Linagliptin, 5 Milligrams Orally, as Add on to Basal Insulin in Elderly Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
September 23, 2014 (Actual)
Primary Completion Date
April 18, 2017 (Actual)
Study Completion Date
April 25, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older, with Type 2 Diabetes Mellitus and insufficient glycaemic control.Stable background therapy of metformin and/or alpha-glucosidase inhibitors is also allowed.
In addition, this trial will assess if linagliptin reduces the risk of hypoglycaemia when added to background basal insulin therapy. The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in glycosylated Haemoglobin, a well-accepted measurement of chronic glycaemic control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
302 (Actual)
8. Arms, Groups, and Interventions
Arm Title
linagliptin 5 mg
Arm Type
Experimental
Arm Description
patient to receive a tablet of linagliptin 5 mg each day
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
patient to receive a tablet of placebo matching linagliptin 5 mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo matching linagliptin 5 mg
Intervention Type
Drug
Intervention Name(s)
linagliptin
Intervention Description
5 mg once a day
Primary Outcome Measure Information:
Title
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.
Description
This outcome has measured difference between HbA1c values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication. HbA1c is a form of hemoglobin, a blood pigment that carries oxygen, which is bound to glucose. The term HbA1c also refers to glycated hemoglobin. High levels of HbA1c (Normal range is less than 6%) indicate poorer control of diabetes than level in normal range.
Time Frame
Baseline and Week 24
Secondary Outcome Measure Information:
Title
Percentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.
Description
Hypoglycaemia accompanied by a prespecified glucose value is defined as any investigator reported hypoglycaemia (event or AE) with a reported blood glucose level of less than 54 milligram/deciLitre (3.0 millimole/Litre) or any investigator reported symptomatic hypoglycaemic AE with a reported blood glucose level of less or equal 70 milligram/deciLitre (3.9millimole/Litre) or any severe hypoglycaemic AE. Severe hypoglycaemia is an event that requires the assistance of another person to actively administer carbohydrates or glucagon because the patient is unable to take the substance on his or her own. The confidence intervals mentioned in measure of dispersion are exact 95% confidence interval by Clopper and Pearson. The percentage of patients with at least one hypoglycaemia accompanied by a glucose value less than 54mg/dL alone has also represented separately according American Diabetes Association definition of clinically significant hypoglycaemia.
Time Frame
24 weeks
Title
Percentage of Patients With HbA1c<8.0%
Description
This is the percentage of patients with HbA1c on treatment <8.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Time Frame
24 weeks
Title
Percentage of Patients With HbA1c on Treatment <7.0%
Description
This is the percentage of patients with HbA1c on treatment <7.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Time Frame
24 weeks
Title
Percentage of Patients With HbA1c Lowering by at Least 0.5%.
Description
The percentage of patients who attained lowering of HbA1c by ≥0.5% from baseline after 24 weeks of treatment were analysed. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Time Frame
24 weeks
Title
Change From Baseline in Fasting Plasma Glucose (FPG)
Description
This outcome has measured difference between FPG values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication
Time Frame
Baseline and Week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation and Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial.
Male and female patients with a clinical diagnosis of Type 2 Diabetes Mellitus, at the time of Informed Consent, who are:
60 years of age or older at informed consent or Screen Visit,
taking stable doses of basal or biosimilar basal insulin [strictly inclusive of: insulin neutral protamine Hagedorn and isophane insulin; Humalog Basal (a suspension of insulin lispro protamine); insulin degludec; insulin detemir; and insulin glargine] for at least 4 weeks prior to randomisation (Visit 3) with dose adjustments up to a maximum of plus or minus 20% of baseline being allowed,
may or may not be taking metformin immediate release or extended release [if the patient is taking metformin, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)], and
may or may not be taking alpha-glucosidase inhibitors [acarbose, miglitol, and voglibose; if the patient is taking alpha-glucosidase inhibitors, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)].
Patients must have an glycosylated Haemoglobin of 7.0% (53 millimoles per mole) to 10.0% (86 millimoles per mole) at the first visit (Screen).
Patients must have a Body Mass Index of 45 kilogram/meter squared or less at the Screen Visit.
In the investigator's opinion, patients must be reliable, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them.
Exclusion criteria:
Impaired cognitive ability as supported by the Saint Louis University Mental Status Examination, additional assessment if necessary, and verified by the investigator at the Screen Visit.
Depressed mood as supported by a score of 10 or more on the Patient Health Questionnaire at the Screen Visit.
Type 1 Diabetes Mellitus as determined by past medical records and history.
Acute coronary syndrome (non-ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, and/or unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to Screen Visit.
Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the upper limit of normal in any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.
Bariatric, gastric bypass, and other gastrointestinal procedures or surgeries (including all types of gastric banding, restriction, and/or LapBand) with the objective of promoting weight loss within the past two years at Screen Visit.
Medical history of cancer (except for resected non-invasive basal or squamous cell carcinoma) and/or treatment for cancer within the last 5 years.
Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (malaria, babesiosis, haemolytic anaemia).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
Syed Research Consultants, LLC
City
Sheffield
State/Province
Alabama
ZIP/Postal Code
35660
Country
United States
Facility Name
Precision Research Institute, LLC
City
Chula Vista
State/Province
California
ZIP/Postal Code
91910
Country
United States
Facility Name
Aurora Care Clinic, LLC
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92627
Country
United States
Facility Name
Prime Care Clinical Research
City
Laguna Hills
State/Province
California
ZIP/Postal Code
92653
Country
United States
Facility Name
Torrance Clinical Research Institute Inc.
City
Lomita
State/Province
California
ZIP/Postal Code
90717
Country
United States
Facility Name
Internal Medicine of the Rockies
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80910
Country
United States
Facility Name
Cohen Medical Research Associates, LLC
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33446
Country
United States
Facility Name
Riverside Clinical Research
City
Edgewater
State/Province
Florida
ZIP/Postal Code
32132
Country
United States
Facility Name
Clinical Research of Hollywood
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
East Coast Institute for Research LLC at NE FL Endo & Diabetes
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
Solutions Through Advanced Research, Inc.
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32258
Country
United States
Facility Name
Panax Clinical Research
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Baptist Diabetes Associates, PA
City
Miami
State/Province
Florida
ZIP/Postal Code
33156
Country
United States
Facility Name
International Research Associates
City
Miami
State/Province
Florida
ZIP/Postal Code
33183
Country
United States
Facility Name
South Florida Research Solutions, LLC
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33026
Country
United States
Facility Name
Georgia Clinical Research, LLC
City
Snellville
State/Province
Georgia
ZIP/Postal Code
30078
Country
United States
Facility Name
Midwest Endocrinology
City
Crystal Lake
State/Province
Illinois
ZIP/Postal Code
60012
Country
United States
Facility Name
American Health Network
City
Avon
State/Province
Indiana
ZIP/Postal Code
46123
Country
United States
Facility Name
Accent Clinical Trials
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89052
Country
United States
Facility Name
Clinical Research of South Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89121
Country
United States
Facility Name
Manhattan Medical Research Practice PLLC
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Family Practice Center of Wadsworth, Inc.
City
Wadsworth
State/Province
Ohio
ZIP/Postal Code
44281
Country
United States
Facility Name
Clinical Research Associates of Central Pennsylvania
City
Altoona
State/Province
Pennsylvania
ZIP/Postal Code
16602
Country
United States
Facility Name
Fleetwood Clinical Research
City
Fleetwood
State/Province
Pennsylvania
ZIP/Postal Code
19522
Country
United States
Facility Name
Preferred Primary Care Phys
City
Uniontown
State/Province
Pennsylvania
ZIP/Postal Code
15401
Country
United States
Facility Name
TLM Medical Services, LLC
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29204
Country
United States
Facility Name
Advanced Research Associates
City
Hodges
State/Province
South Carolina
ZIP/Postal Code
29653
Country
United States
Facility Name
Holston Medical Group
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Arlington Family Research Center, Inc.
City
Arlington
State/Province
Texas
ZIP/Postal Code
76012
Country
United States
Facility Name
Renaissance Clinical Research and Hypertension of Texas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75234
Country
United States
Facility Name
Diabetes and Thyroid Center of Fort Worth
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76132
Country
United States
Facility Name
Houston Clinical Research Associates
City
Houston
State/Province
Texas
ZIP/Postal Code
77090
Country
United States
Facility Name
Science Advancing Medicine Clinical Research Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Office of Dr. Val R. Hansen
City
Bountiful
State/Province
Utah
ZIP/Postal Code
84010
Country
United States
Facility Name
Millennium Clinical Trials LLC
City
Arlington
State/Province
Virginia
ZIP/Postal Code
22203
Country
United States
Facility Name
York Clinical Research, LLC
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States
Facility Name
Rowan Research, Inc.
City
Spokane
State/Province
Washington
ZIP/Postal Code
99218
Country
United States
Facility Name
Family Medical Clinic
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53216
Country
United States
Facility Name
AIM Centre
City
Merewether
State/Province
New South Wales
ZIP/Postal Code
2291
Country
Australia
Facility Name
Royal Brisbane & Women's Hospital-Endocrinology
City
Herston
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Facility Name
ECRU Maroondah
City
East Ringwood
State/Province
Victoria
ZIP/Postal Code
3135
Country
Australia
Facility Name
Ham - PRAC Mortelmans
City
Oostham
ZIP/Postal Code
3945
Country
Belgium
Facility Name
CEQUIN
City
Armenia
ZIP/Postal Code
630004
Country
Colombia
Facility Name
Dexa Diabetes Servicios Médicos Ltda
City
Bogotá
ZIP/Postal Code
110221
Country
Colombia
Facility Name
CAFAM Caja de Compensación Familiar
City
Bogotá
ZIP/Postal Code
111211
Country
Colombia
Facility Name
Asociacion IPS Medicos Internistas de Caldas
City
Manizales
ZIP/Postal Code
170004
Country
Colombia
Facility Name
Hospital Pablo Tobón Uribe
City
Medellín
ZIP/Postal Code
050034
Country
Colombia
Facility Name
Aalborg Sygehus Syd
City
Aalborg
ZIP/Postal Code
9100
Country
Denmark
Facility Name
Sydvestjyst Sygehus Esbjerg, Endokrinologisk afdeling
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Facility Name
Frederiksberg Hospital, Endokrinologisk afd.
City
Frederiksberg
ZIP/Postal Code
2000
Country
Denmark
Facility Name
Gentofte University Hospital
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Kolding Sygehus
City
Kolding
ZIP/Postal Code
6000
Country
Denmark
Facility Name
Bispebjerg Hospital
City
København NV
ZIP/Postal Code
2400
Country
Denmark
Facility Name
Køge Sygehus
City
Køge
ZIP/Postal Code
4600
Country
Denmark
Facility Name
Roskilde Sygehus
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark
Facility Name
Keravan terveyskeskus
City
Kerava
ZIP/Postal Code
04200
Country
Finland
Facility Name
Terveystalo Oulu, Diapolis
City
Oulu
ZIP/Postal Code
FI-90100
Country
Finland
Facility Name
Lääkärikeskus Aava, Turku
City
Turku
ZIP/Postal Code
20520
Country
Finland
Facility Name
TYKS
City
Turku
ZIP/Postal Code
FI-20520
Country
Finland
Facility Name
Gemeinschaftspraxis, Asslar
City
Asslar
ZIP/Postal Code
35614
Country
Germany
Facility Name
ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH
City
Berlin
ZIP/Postal Code
10115
Country
Germany
Facility Name
Diabetologische Schwerpunktpraxis, Bosenheim
City
Bosenheim
ZIP/Postal Code
55545
Country
Germany
Facility Name
Dünnwaldpraxis, Köln
City
Koeln
ZIP/Postal Code
51069
Country
Germany
Facility Name
Praxis Dr. Naudts, Rodgau
City
Rodgau
ZIP/Postal Code
63110
Country
Germany
Facility Name
Praxis Dr. Braun, Unterschneidheim
City
Unterschneidheim
ZIP/Postal Code
73485
Country
Germany
Facility Name
"Korgialeneio-Benakeio" Hellenic Red Cross Hospital
City
Athens
ZIP/Postal Code
115 26
Country
Greece
Facility Name
General Hospital of Athens "G. Gennimatas"
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
Univ. Gen. Hosp. of Ioannina
City
Ioannina
ZIP/Postal Code
45500
Country
Greece
Facility Name
General Hospital of Attiki "KAT-EKA"
City
Kifisia
ZIP/Postal Code
14561
Country
Greece
Facility Name
General Hospital of Nikaia
City
Nikaia
ZIP/Postal Code
18454
Country
Greece
Facility Name
General Hospital of Thessaloniki "G. Papanikolaou"
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Facility Name
Connolly Hospital Blanchardstown
City
Dublin
ZIP/Postal Code
Dublin 15
Country
Ireland
Facility Name
Daishinkai Medical Corporation Ookuma Hospital
City
Aichi, Nagoya
ZIP/Postal Code
462-0825
Country
Japan
Facility Name
Matsuyama Shimin Hospital
City
Ehime, Matsuyama
ZIP/Postal Code
790-0067
Country
Japan
Facility Name
Iryohojin Kikuchi Naika Clinic
City
Gunma, Maebashi
ZIP/Postal Code
370-3573
Country
Japan
Facility Name
Nakamura Digestive Organ Internal Medicine Clinic
City
Hokkaido, Bibai
ZIP/Postal Code
072-0012
Country
Japan
Facility Name
Iida Medical Clinic
City
Hokkaido, Hakodate
ZIP/Postal Code
042-0942
Country
Japan
Facility Name
Jiyugaoka Yamada Clinic
City
Hokkaido, Obihiro
ZIP/Postal Code
080-0848
Country
Japan
Facility Name
Shinkotoni family Clinic
City
Hokkaido, Sapporo
ZIP/Postal Code
001-0912
Country
Japan
Facility Name
Yoshida Memorial Hospital
City
Hokkaido, Sapporo
ZIP/Postal Code
003-0026
Country
Japan
Facility Name
Teine Keijinkai Clinic
City
Hokkaido, Sapporo
ZIP/Postal Code
006-0811
Country
Japan
Facility Name
Japan Community Health Care Organization Hokkaido Hospital
City
Hokkaido, Sapporo
ZIP/Postal Code
062-8618
Country
Japan
Facility Name
Itabashi Diabetic medicine and Dermatology Clinic
City
Ibaraki, Koga
ZIP/Postal Code
306-0232
Country
Japan
Facility Name
Nakakinen Clinic
City
Ibaraki, Naka
ZIP/Postal Code
311-0113
Country
Japan
Facility Name
Takai Naika Clinic
City
Kanagawa, Kamakura
ZIP/Postal Code
247-0056
Country
Japan
Facility Name
Kaneshiro DIAB Clinic, Kanagawa, I.M.
City
Kanagawa, Sagamihara
ZIP/Postal Code
252-0302
Country
Japan
Facility Name
Asahi Med. clinic, Kanagawa, I.M.
City
Kanagawa, Yokohama
ZIP/Postal Code
221-0802
Country
Japan
Facility Name
Ishikawa Med. Clinic, Kanagawa, I.M.
City
Kanagawa, Yokohama
ZIP/Postal Code
241-0821
Country
Japan
Facility Name
National Hospital Organization Yokohama Medical Center
City
Kanagawa, Yokohama
ZIP/Postal Code
245-8575
Country
Japan
Facility Name
Okayama Saiseikai General Hospital Outpatient Center
City
Okayama, Okayama
ZIP/Postal Code
700-8511
Country
Japan
Facility Name
AMC Nishi-umeda Clinic
City
Osaka, Osaka
ZIP/Postal Code
530-0001
Country
Japan
Facility Name
Nissay Hospital Nippon Life Saiseikai Public Interest Incorporated Foundation
City
Osaka, Osaka
ZIP/Postal Code
550-0012
Country
Japan
Facility Name
OCROM Clinic
City
Osaka, Suita
ZIP/Postal Code
565-0853
Country
Japan
Facility Name
Saga Memorial Hospital
City
Saga, Saga
ZIP/Postal Code
849-0917
Country
Japan
Facility Name
Asano Clinic
City
Saitama, Kawagoe
ZIP/Postal Code
350-0851
Country
Japan
Facility Name
Hamamatsu Rosai Hospital
City
Shizuoka, Hamamatsu
ZIP/Postal Code
430-8525
Country
Japan
Facility Name
Kuriyama Clinic
City
Tokyo, Adachi-ku
ZIP/Postal Code
121-0064
Country
Japan
Facility Name
The Institute for Adult Deseases, Asahi Life Foundation
City
Tokyo, Chuo-ku
ZIP/Postal Code
103-0002
Country
Japan
Facility Name
Tokyo-Eki Center-building Clinic
City
Tokyo, Chuo-ku
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Tokyo Center Clinic
City
Tokyo, Chuo-ku
ZIP/Postal Code
103-0028
Country
Japan
Facility Name
AGE Makita Medical Clinic
City
Tokyo, Chuo-ku
ZIP/Postal Code
104-0061
Country
Japan
Facility Name
Kobayashi Internal Medicine Clinic
City
Tokyo, Koto-ku
ZIP/Postal Code
135-0011
Country
Japan
Facility Name
Kunitachi Naika Clinic
City
Tokyo, Kunitachi
ZIP/Postal Code
186-0002
Country
Japan
Facility Name
Japanese Red Cross Medical Center
City
Tokyo, Shibuya-ku
ZIP/Postal Code
150-8935
Country
Japan
Facility Name
Investigación en Salud y Metabolismo S.C.
City
Chihuahua
ZIP/Postal Code
31217
Country
Mexico
Facility Name
Centro de At. e Inv.en Fact.de riesgo cardiovasc.Omega, S.C.
City
Mexico
ZIP/Postal Code
06400
Country
Mexico
Facility Name
CAIMED
City
Mexico
ZIP/Postal Code
06760
Country
Mexico
Facility Name
Clinstile S.A. de C.V.
City
México
ZIP/Postal Code
06700
Country
Mexico
Facility Name
CEDOPEC-Ctro Esp en Diab, Obesidad y Prev de Enf Cardiovasc
City
México
ZIP/Postal Code
C.P. 11650
Country
Mexico
Facility Name
Asociación Mexicana para la Investigacion Clínica, A.C(AMIC)
City
Pachuca
ZIP/Postal Code
42070
Country
Mexico
Facility Name
South Pacific Clinical Trials
City
Auckland, New Zealand
ZIP/Postal Code
0610
Country
New Zealand
Facility Name
Middlemore Clinical Trials
City
Auckland
ZIP/Postal Code
2025
Country
New Zealand
Facility Name
Christchurch Hospital
City
Christchurch
ZIP/Postal Code
8011
Country
New Zealand
Facility Name
Medicome Sp. z o.o.
City
Oswiecim
ZIP/Postal Code
32-600
Country
Poland
Facility Name
Omedica Centrum Medyczne
City
Poznan
ZIP/Postal Code
60-111
Country
Poland
Facility Name
NBR Polska
City
Warszawa
ZIP/Postal Code
00-465
Country
Poland
Facility Name
Nicodiab SRL, Bucharest
City
Bucharest
ZIP/Postal Code
010507
Country
Romania
Facility Name
Pelican Impex SRL, Cabinet Nr. 15
City
Oradea
ZIP/Postal Code
410469
Country
Romania
Facility Name
Mediab SRL
City
Tirgu Mures
ZIP/Postal Code
540142
Country
Romania
Facility Name
TREAD Research
City
Cape Town
ZIP/Postal Code
7500
Country
South Africa
Facility Name
Tiervlei Trial Centre
City
Cape Town
ZIP/Postal Code
7530
Country
South Africa
Facility Name
Paarl Research Centre
City
Cape Town
ZIP/Postal Code
7646
Country
South Africa
Facility Name
Soweto Clinical Trials Centre
City
Johannesburg
ZIP/Postal Code
1818
Country
South Africa
Facility Name
LCS Clinical Research Unit
City
Johannesburg
ZIP/Postal Code
2021
Country
South Africa
Facility Name
Resego Health Services
City
Johannesburg
ZIP/Postal Code
2189
Country
South Africa
Facility Name
Zinakekele Medical Centre
City
KwaMhlanga
ZIP/Postal Code
1022
Country
South Africa
Facility Name
Mzansi Ethical Research Centre
City
Middleburg
ZIP/Postal Code
1055
Country
South Africa
Facility Name
VX Pharma (Pty) Ltd Pretoria
City
Pretoria
ZIP/Postal Code
0087
Country
South Africa
Facility Name
Hospital A Coruña
City
A Coruña
ZIP/Postal Code
15003
Country
Spain
Facility Name
Instituto de Ciencias Médicas
City
Alicante
ZIP/Postal Code
03004
Country
Spain
Facility Name
Hospital Quiron. I.C.U.
City
Barcelona
ZIP/Postal Code
08023
Country
Spain
Facility Name
C.A.P. Sardenya
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
CAP Les Corts
City
Barcelona
ZIP/Postal Code
08028
Country
Spain
Facility Name
CAP Canet de Mar
City
Canet de Mar
ZIP/Postal Code
08360
Country
Spain
Facility Name
Hospital Virgen de la Victoria
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Nuestra Señora de Valme
City
Sevilla
ZIP/Postal Code
41014
Country
Spain
Facility Name
Hospital Clínico de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
CAP El Remei
City
Vic
ZIP/Postal Code
08500
Country
Spain
Facility Name
The Haven Surgery
City
Burnhope
ZIP/Postal Code
DH7 0BD
Country
United Kingdom
Facility Name
South Axholme Practice
City
Doncaster
ZIP/Postal Code
DN9 2HY
Country
United Kingdom
Facility Name
Fowey Clinical Research Company Ltd
City
Fowey
ZIP/Postal Code
PL23 1DT
Country
United Kingdom
Facility Name
Oak Tree Surgery
City
Liskeard
ZIP/Postal Code
PL14 3XA
Country
United Kingdom
Facility Name
St. Mary's Hospital, Vectasearch Clinic, Newport
City
Newport
ZIP/Postal Code
PO309 5TG
Country
United Kingdom
Facility Name
Mounts Bay Medical Ltd
City
Penzance
ZIP/Postal Code
TR19 7HX
Country
United Kingdom
Facility Name
Rame Medical, Penntorr Health
City
Torpoint
ZIP/Postal Code
PL11 2TB
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
31482511
Citation
Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged >/= 60 Years Treated with Basal Insulin: A Randomised Trial. Adv Ther. 2019 Oct;36(10):2697-2711. doi: 10.1007/s12325-019-01065-7. Epub 2019 Sep 3.
Results Reference
derived
Learn more about this trial
Linagliptin as Add on to Basal Insulin in the Elderly
We'll reach out to this number within 24 hrs